Phathom Pharmaceuticals, Inc. (PHAT) Dividend History

Company News

• Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

  Phathom Pharmaceuticals, a biopharmaceutical company, announced the appointment of Ted Schroeder, a seasoned biopharma leader, to its Board of Directors. Schroeder's deep operational and commercial expertise is expected to be an important asset as Phathom continues to unlock the full potential of its lead product, VOQUEZNA.

  GlobeNewswire Inc.
• Phathom Pharmaceuticals Announces Leadership Succession

  Phathom Pharmaceuticals has appointed Steven Basta as its new President and CEO, succeeding Terrie Curran. Basta is an experienced biopharmaceutical leader who will focus on accelerating the commercial growth of Phathom's lead product, VOQUEZNA.

  GlobeNewswire Inc.
• Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

  Phathom Pharmaceuticals reported strong commercial performance for its GERD treatment VOQUEZNA, with $55.3 million in 2024 net revenues and over 300,000 filled prescriptions. The company also announced plans to initiate a Phase 2 trial for VOQUEZNA in eosinophilic esophagitis.

  GlobeNewswire Inc.
• Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

  Phathom Pharmaceuticals, a biopharmaceutical company focused on gastrointestinal diseases, announced that members of its management team will participate in a fireside chat and one-on-one meetings at the Guggenheim Securities SMID Cap Biotech Conference.

  GlobeNewswire Inc.
• Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

  Phathom Pharmaceuticals, a biopharmaceutical company, will host a live webcast on November 7, 2024, to report its third quarter 2024 financial results and provide a business update.

  GlobeNewswire Inc.